Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7232238 | 1.00 | TACR1 (0.50) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6590252 | 0.99 | TACR1 (0.49) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4940221 | 0.95 | TACR1 (0.44) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL5414703 | 0.73 | TACR1 (0.34) | TACR1CYP2D6 | |
| SCHEMBL5159312 | 0.72 | TACR1 (0.33) | TACR1CYP2D6 | |
| SCHEMBL7162519 | 0.71 | TACR1 (0.54) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7134191 | 0.71 | TACR1 (0.54) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL22570225 | 0.67 | TACR1 (0.52) | TACR1CYP2D6KCNH2 | |
| SCHEMBL22570228 | 0.67 | TACR1 (0.52) | TACR1CYP2D6KCNH2 | |
| SCHEMBL22570227 | 0.67 | TACR1 (0.52) | TACR1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167200-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2004-08-26 | — | — | US | claimed |
| EP-1404320-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT FOR MODULATING CHOLINERGIC FUNCTION | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | claimed |
| US-20030133951-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| WO-2003005998-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT OF MODULATING CHOLINERGIC FUNCTION | PFIZER PRODUCTS INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-20030008892-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2003-01-09 | — | — | US | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| US-20010036943-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040220274-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040167200-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1404320-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT FOR MODULATING CHOLINERGIC FUNCTION | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1178984-A2 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| EP-1099446-A2 | Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1095655-A2 | NK-1 receptor antagonists and eletriptan for the treatment of migraine | Pfizer Products Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-1095939-A2 | Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds | Pfizer Products Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000071538-A2 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885CYP2D6 1323/4885KCNH2 158/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | TACR1 5/4885CYP2D6 1204/4885KCNH2 158/4885 |
| US-20040220274-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885CYP2D6 1241/4885KCNH2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.